Cyclo-(Phe-Tyr) as a novel cyclic dipeptide compound alleviates ischemic/reperfusion brain injury via JUNB/JNK/NF-&#954;B and SOX5/PI3K/AKT pathways.

Cai, Jiale; Liang, Jiayin; Zhang, Yutong; Shen, Lin; Lin, Huiting; Hu, Tao; Zhan, Sikai; Xie, Meixia; Liang, Shengwang; Xian, Minghua; Wang, Shumei

Cyclo-(Phe-Tyr) as a novel cyclic dipeptide compound alleviates ischemic/reperfusion brain injury via JUNB/JNK/NF-κB and SOX5/PI3K/AKT pathways.

Cai, Jiale; Liang, Jiayin; Zhang, Yutong; Shen, Lin; Lin, Huiting; Hu, Tao; Zhan, Sikai; Xie, Meixia; Liang, Shengwang; Xian, Minghua; Wang, Shumei.

Afiliação

Cai J; Guangdong Pharmaceutical University, Guangzhou 510006, China; Key Laboratory of Digital Quality Evaluation of Chinese Materia Medica of State Administration of TCM, Guangzhou 510006, China; Engineering & Technology Research Center for Chinese Materia Medica Quality of the Universities of Guangdo
Liang J; Guangdong Pharmaceutical University, Guangzhou 510006, China; Key Laboratory of Digital Quality Evaluation of Chinese Materia Medica of State Administration of TCM, Guangzhou 510006, China; Engineering & Technology Research Center for Chinese Materia Medica Quality of the Universities of Guangdo
Zhang Y; Guangdong Pharmaceutical University, Guangzhou 510006, China.
Shen L; Guangdong Pharmaceutical University, Guangzhou 510006, China; Key Laboratory of Digital Quality Evaluation of Chinese Materia Medica of State Administration of TCM, Guangzhou 510006, China; Engineering & Technology Research Center for Chinese Materia Medica Quality of the Universities of Guangdo
Lin H; Guangdong Pharmaceutical University, Guangzhou 510006, China; Key Laboratory of Digital Quality Evaluation of Chinese Materia Medica of State Administration of TCM, Guangzhou 510006, China; Engineering & Technology Research Center for Chinese Materia Medica Quality of the Universities of Guangdo
Hu T; Guangdong Pharmaceutical University, Guangzhou 510006, China; Key Laboratory of Digital Quality Evaluation of Chinese Materia Medica of State Administration of TCM, Guangzhou 510006, China; Engineering & Technology Research Center for Chinese Materia Medica Quality of the Universities of Guangdo
Zhan S; Guangdong Pharmaceutical University, Guangzhou 510006, China; Key Laboratory of Digital Quality Evaluation of Chinese Materia Medica of State Administration of TCM, Guangzhou 510006, China; Engineering & Technology Research Center for Chinese Materia Medica Quality of the Universities of Guangdo
Xie M; Guangdong Pharmaceutical University, Guangzhou 510006, China; Key Laboratory of Digital Quality Evaluation of Chinese Materia Medica of State Administration of TCM, Guangzhou 510006, China; Engineering & Technology Research Center for Chinese Materia Medica Quality of the Universities of Guangdo
Liang S; Guangdong Pharmaceutical University, Guangzhou 510006, China; Key Laboratory of Digital Quality Evaluation of Chinese Materia Medica of State Administration of TCM, Guangzhou 510006, China; Engineering & Technology Research Center for Chinese Materia Medica Quality of the Universities of Guangdo
Xian M; Guangdong Pharmaceutical University, Guangzhou 510006, China; Key Laboratory of Digital Quality Evaluation of Chinese Materia Medica of State Administration of TCM, Guangzhou 510006, China; Engineering & Technology Research Center for Chinese Materia Medica Quality of the Universities of Guangdo
Wang S; Guangdong Pharmaceutical University, Guangzhou 510006, China; Key Laboratory of Digital Quality Evaluation of Chinese Materia Medica of State Administration of TCM, Guangzhou 510006, China; Engineering & Technology Research Center for Chinese Materia Medica Quality of the Universities of Guangdo

Pharmacol Res ; 180: 106230, 2022 06.

Article em En | MEDLINE | ID: mdl-35483515

Assuntos

Lesões Encefálicas; Traumatismo por Reperfusão; Animais; Encéfalo/metabolismo; Lesões Encefálicas/metabolismo; Dipeptídeos/metabolismo; Dipeptídeos/farmacologia; Dipeptídeos/uso terapêutico; Inflamação/tratamento farmacológico; NF-kappa B/metabolismo; Fosfatidilinositol 3-Quinases/metabolismo; Proteínas Proto-Oncogênicas c-akt/metabolismo; Ratos; Reperfusão; Traumatismo por Reperfusão/tratamento farmacológico; Traumatismo por Reperfusão/metabolismo

Palavras-chave

1-Deoxy-1-(N6-lysino)-D-fructose (PubChem CID: 433981164); 10Z; 13Z; 16Z)/16:0) (PubChem CID: 52923621); 2-O-(5,8,11,14,17-Eicosapentaenoyl)− 1-O-hexadecylglycero-3-phosphocholine (PubChem CID: 10485310); Alanyl-Arginine (PubChem CID: 446132); Cyclo(Tyr-Phe) (PubChem CID: 44198062); Cyclo-(Phe-Tyr); Diacetone alcohol (PubChem CID: 31256); Homoanserine (PubChem CID: 20849429); Ischemic/reperfusion; JUNB; Metabolomics; Methyl jasmonate (PubChem CID: 5281929); PC (16:0/15:0) (PubChem CID: 24778680); PC(22:4(7Z; PC(P-18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) (PubChem CID: 53480781); RNA-sequence; SATB1; SATB2; SOX5

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Lesões Encefálicas / Traumatismo por Reperfusão Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google